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Abstract
Practical application of genomic-based risk stratification to clinical diagnosis is appealing yet performance varies widely
depending on the disease and genomic risk score (GRS) method. Celiac disease (CD), a common immune-mediated illness, is
strongly genetically determined and requires specific HLA haplotypes. HLA testing can exclude diagnosis but has low
specificity, providing little information suitable for clinical risk stratification. Using six European cohorts, we provide a proof-
of-concept that statistical learning approaches which simultaneously model all SNPs can generate robust and highly
accurate predictive models of CD based on genome-wide SNP profiles. The high predictive capacity replicated both in cross-
validation within each cohort (AUC of 0.87–0.89) and in independent replication across cohorts (AUC of 0.86–0.9), despite
differences in ethnicity. The models explained 30–35% of disease variance and up to ,43% of heritability. The GRS’s utility
was assessed in different clinically relevant settings. Comparable to HLA typing, the GRS can be used to identify individuals
without CD with $99.6% negative predictive value however, unlike HLA typing, fine-scale stratification of individuals into
categories of higher-risk for CD can identify those that would benefit from more invasive and costly definitive testing. The
GRS is flexible and its performance can be adapted to the clinical situation by adjusting the threshold cut-off. Despite
explaining a minority of disease heritability, our findings indicate a genomic risk score provides clinically relevant
information to improve upon current diagnostic pathways for CD and support further studies evaluating the clinical utility
of this approach in CD and other complex diseases.
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Introduction
Improving the diagnosis of celiac disease (CD), a common
immune-mediated illness caused by dietary gluten, remains a
clinical challenge [1,2]. Despite a prevalence of approximately 1%
in most Western countries, lack of awareness and failure to
implement appropriate serological, histological and genetic testing
means that less than 30–40% of those affected by CD are diagnosed
[1,3–5]. Undiagnosed CD is associated with reduced quality of life,
substantial morbidity, and increased mortality, however, prompt
diagnosis and treatment lowers the burden of disease and may
reduce the rate of complications such as osteoporosis, autoimmune
disease, and malignancy. Optimizing the diagnosis of CD is now
recognized as an important goal for clinicians [6].
CD is characterized by a variable combination of gluten-
dependent clinical manifestations, CD-specific antibodies and small
bowel inflammation (villous atrophy) [7]. Traditional guidelines for
the diagnosis of CD rely on demonstrating villous atrophy and
improvement of symptoms, laboratory abnormalities, and/or small
bowel inflammation upon exclusion of dietary gluten [8]. Current
clinical practice is to screen for CD by detecting CD-specific serum
antibodies and then confirm the diagnosis by undertaking small
bowel biopsy to demonstrate typical villous atrophy. Serologic
screening for CD with transglutaminase-IgA antibodies is reported
to be highly sensitive and specific for CD (both.90%), imparting a
high positive predictive value (PPV) of over 90% when assessing
most populations [9,10], although the PPV can fall to 45–70% in
community screening settings [11,12]. In practice, serological and
histological assessments have technical limitations that generate
both false negative and false positive diagnoses.
A key feature of CD is its strong dependence on the presence of
susceptibility genes encoding for HLA DQ2.5, DQ8, and/or half
the HLA DQ2.5 heterodimer (typically DQ2.2), seen in approx-
imately 99.6% of all patients with CD [13]. These genes encode
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immune-recognition molecules which facilitate CD4+ T cell
recognition of specific gluten-derived peptides, a critical step in
disease pathogenesis [14–18]. Recognizing the crucial role of these
genes, the latest consensus diagnostic guidelines for CD recom-
mend testing for these HLA heterodimers (HLA typing) as a first-
line investigation for asymptomatic individuals identified at-risk of
CD, such as 1st-degree relatives of an affected individual or those
with suggestive symptoms [7]. However, a major flaw of HLA
typing as a diagnostic tool is that a substantial proportion of the
community, typically reported to be 30–40%, express HLA
DQ2.5, DQ8, and/or DQ2.2, thus making the presence of these
HLA types poorly predictive and of low specificity for CD [13].
Indeed, a recent Australian population study revealed that 56% of
the community possessed at least one of these CD susceptibility
haplotypes [5]. Thus, while HLA typing can exclude CD in the
community with high confidence when the susceptibility haplo-
types are absent, these haplotypes will be present in 30–56% of the
population, the majority of whom would not have CD. Therefore,
if assessed as a stand-alone test, HLA typing has exceptionally high
sensitivity and negative predictive value (NPV) but very poor
specificity and low positive predictive value (PPV) for CD. Since a
positive result poorly predicts the presence of CD, HLA typing is
not useful as a stand-alone diagnostic tool for CD. While the
relative-risk for CD can be stratified based on the HLA subtype
(CD risk DQ2.5.DQ8.DQ2.2) [19], these categories have low
positive predictive value and do not provide clinically-informative
attribution of CD risk [20]; HLA results are therefore interpreted
as a binary outcome: CD susceptibility positive or negative.
Despite these limitations, HLA typing is now widely utilized in
clinical practice and typically determined using polymerase chain-
reaction sequence specific oligonucleotide (PCR-SSO) hybridiza-
tion, which is time and labor intensive, and costly (AU $120/
sample, Medicare; in the USA cost varies but is typically US $150/
sample or greater).
It is important to distinguish between three different approaches
to analyzing the HLA region for association with CD. The first
approach, currently in clinical practice, is HLA typing, as
described above, where the HLA result is considered a binary
variable and its utility is to exclude CD. A second approach, such
as that taken by Romanos et al., utilizes the same HLA-DQ
haplotypes, stratifies individuals into several nominal risk levels
then fits a statistical model to empirically estimate the true risk in
each group [21,22]. While HLA-DQ haplotypes may be inferred
from typing several HLA SNPs, importantly the HLA SNPs are
only used to assign the HLA type and the SNPs themselves are not
directly modeled. The third approach, such as that used here, is
based on direct concurrent modeling of many thousands of
individual SNPs for association with CD in order to produce a
more fine-grained predictive ‘‘genomic risk score’’ (GRS).
GRSs have been enabled by the advent of genome-wide
association studies (GWAS), which perform unbiased testing of
many thousands of SNPs for association with CD. Using GWAS,
recent studies have identified multiple non-HLA SNP associations
with CD [23,24]. GWAS are primarily concerned with the
detection of variants associated with disease in order to gain insight
into the disease etiology and genetic architecture. Due to the high
number of significance tests, controlling for false positive
associations is a major, valid concern. Therefore, SNP-based risk
scores have tended to be constructed from the SNPs found to be
significantly associated with the disease status [22,25]. However,
due to the stringent multiple-testing corrections utilized in GWAS
there may be other SNPs that fail to achieve genome-wide
significance but may be predictive of disease status nonetheless and
including them in the model could potentially result in higher
predictive ability than achievable by models based solely on
genome-wide significant SNPs. In contrast to the GWAS
approach, the main overriding aim of a GRS from a clinical
perspective is to achieve maximal predictive capacity, the
inference of genetic architecture is secondary.
We have recently designed computational algorithms which
efficiently fit L1-penalized multivariable classification models to
genome-wide and whole-genome SNP data [26]. Such models
were then shown to be preferable to several other methods such as
the standard method of summing the per-SNP log odds (polygenic
score) [27], mixed effects linear modeling [28,29], and unpena-
lized logistic regression, with both better precision for detecting
causal SNPs in simulation and better case/control predictive
power [30]. These advantages were consistent across several
complex diseases, including two British studies of CD. However,
the diagnostic implications of penalized models have not been
previously examined nor has the robustness of such models in
other populations or the advantage over HLA-typing approaches.
In contrast to existing studies that examine a small number of
genome-wide significant SNPs, we have shown that many more
SNPs (potentially hundreds) are required to achieve optimal
predictive ability for CD. Further, the standard GWAS approach
of considering each SNP separately when estimating its effect size
does not consider its correlation with other SNPs. We have shown
that unpenalized predictive models based on these top SNPs suffer
from lower predictive ability than L1-penalized models since the
pre-screening introduces multiple highly correlated SNPs into the
model, of which a substantial proportion may be redundant in
terms of contribution to the predictive ability. Similar L1-
penalized approaches have also recently been successfully applied
to inflammatory bowel disease case/control Immunochip data,
where models based on several hundred SNPs have led to high
predictive ability [31].
Here, we provide a proof-of-concept that the GRS for CD,
induced by L1-penalized support vector machine models, are able
to achieve a predictive capacity and robustness that provides
information not afforded by current diagnostic pathways utilizing
Author Summary
Celiac disease (CD) is a common immune-mediated illness,
affecting approximately 1% of the population in Western
countries but the diagnostic process remains sub-optimal.
The development of CD is strongly dependent on specific
human leukocyte antigen (HLA) genes, and HLA testing to
identify CD susceptibility is now commonly undertaken in
clinical practice. The clinical utility of HLA typing is to
exclude CD when the CD susceptibility HLA types are
absent, but notably, most people who possess HLA types
imparting susceptibility for CD never develop CD. There-
fore, while genetic testing in CD can overcome several
limitations of the current diagnostic tools, the utility of
HLA typing to identify those individuals at increased-risk of
CD is limited. Using large datasets assaying single
nucleotide polymorphisms (SNPs), we have developed
genomic risk scores (GRS) based on multiple SNPs that can
more accurately predict CD risk across several populations
in ‘‘real world’’ clinical settings. The GRS can generate
predictions that optimize CD risk stratification and
diagnosis, potentially reducing the number of unnecessary
follow-up investigations. The medical and economic
impact of improving CD diagnosis is likely to be significant,
and our findings support further studies into the role of
personalized GRS’s for other strongly heritable human
diseases.
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HLA typing alone. This GRS has the potential to provide greater
clinical diagnostic utility by enabling each individual to be
assigned a more informative risk score beyond the simple
designation of ‘‘CD susceptible’’ or ‘‘CD non-susceptible’’, or
‘‘high risk’’ versus ‘‘low risk’’. To enable useful comparisons
between diagnostic approaches, we model the GRS as a stand-
alone test to ‘‘diagnose’’ CD, while at the same time acknowledg-
ing that real world clinical practice will need to draw upon clinical
history, CD-specific serology and small bowel histology to confirm
the diagnosis of CD. We assess the predictive power of the GRS
both in cross-validation and in external validation, across six
different European cohorts, showing that the models strongly
replicate. We test our GRS on three other autoimmune diseases:
type 1 diabetes, Crohn’s disease, and rheumatoid arthritis, finding
some predictive ability for T1D status but none for the others, thus
largely supporting the specificity of the scores for CD. To
overcome limitations of previous studies utilizing GWAS case/
control studies, where ascertainment bias incurs substantially
higher rates of false positive results, we undertake genomic
prediction of CD in ‘‘real world’’ settings where the prevalence of
CD is far lower and evaluate the performance of the GRS using
PPV and NPV at several levels of CD prevalence. Unlike HLA
typing, the GRS allows flexibility in determining who is considered
at higher risk for CD by selecting a clinically determined user-
specified threshold. We demonstrate how these scores can be
practically applied at various prevalence levels to optimize
sensitivity and precision. Finally, we show how the model can be
calibrated to produce accurate predicted probabilities of disease.
Results
An overview of our analysis workflow is shown in Figure 1. We
analyzed five CD datasets on the Illumina Infinium array
platform: UK1 and UK2 (British descent), Finn (Finnish descent),
IT (Italian descent), and NL (Dutch descent). We also utilized a
dataset run on a fine-mapping array: IMM (Immunochip of British
descent) (see Methods and Table 1). We have previously analyzed
the AUC achievable in the UK1 and UK2 [30].
We trained L1-penalized support vector machines (SVM) [26]
on the genotype data, including all post quality control (QC)
autosomal SNPs unless otherwise indicated. These models are
sparse models, (Methods) and varying the penalty induces models
based on different number of SNPs with non-zero coefficients. We
investigated the performance for various degrees of sparsity, and
the models were fitted to all SNPs across the genome simulta-
neously. For each model’s induced risk score, we estimated the
area under the receiver operating characteristic curve (AUC) and
the explained phenotypic variance [32], which depends on the
assumed prevalence of disease.
Cross-Validation in Each Dataset
Within each dataset, we used 10610 fold cross-validation to
estimate the AUC and explained phenotypic variance on the
liability scale. The explained phenotypic variance was derived
from the AUC assuming a population prevalence of K=1%. All
cohorts showed high AUC in cross-validation (Figure 2a), with the
Finnish and Italian cohorts having a maximum of 0.89, followed
by the UK1 cohort (AUC=0.88), and finally the UK2 and Dutch
cohorts with a maximum AUC of 0.87. Both the UK1 and the
Italian cohorts peaked at ,64 SNPs with non-zero weights,
whereas the rest peaked at ,250 SNPs. Subsampling of the
individuals in the UK2 dataset indicated diminishing returns with
80% of the sample size having the same AUC as 100% (Figure
S1). Consistent with this, combining the UK1 and UK2 datasets
did not increase AUC beyond UK2 alone (results not shown). It is
also important to note that some of the control samples were
population-based and were not explicitly screened for celiac
disease, thus ,1% may be cryptic CD cases which potentially
underestimates prediction performance in downstream analyses.
These AUCs correspond to explained phenotypic variance of 30–
35% (Figure 2b). Assuming a CD heritability of 80%, this
translated to an explained genetic variance of 37–43%.
External Validation between Datasets
While cross-validation provides an estimate of the model’s
ability to generalize to unseen datasets, choosing the model with
the highest AUC may lead to so-called ‘‘optimization bias’’ (also
called ‘‘winner’s curse’’) [33,34], potentially manifesting as lower
performance in independent validation. Additionally, cross-vali-
dation cannot compensate for intra-dataset batch effects, as these
would be present in both the training and testing folds, potentially
artificially inflating the apparent predictive ability. To assess
whether the models suffered from optimization bias and to control
for the possibility of intra-dataset batch effects, we performed
external validation. Based on the results of the cross-validation, we
selected the best models trained on the UK2 dataset then, without
any further tuning, tested them on the UK1, Finn, IT and NL
datasets and computed the receiver-operating characteristic
(ROC) curves (Figure 3a). Overall, the models trained on the
UK2 cohort showed high reproducibility on the other cohorts,
achieving AUC of 0.89–0.9 in the Finnish and UK1 datasets,
indicating negligible optimization bias from the cross-validation
procedure. We also examined the replication of different SNP sets
(all autosomal, MHC, and non-MHC) trained on the UK2 dataset
and tested on the others (Figure S2). The trends observed in cross-
validation, namely similar performance for MHC and all
autosomal SNPs and lower but still substantial performance of
non-MHC SNPs, was observed in all external validation
experiments.
Comparison of Genomic Risk Score with Methods Based
on HLA Typing
Since HLA typing is commonly used for assessing CD risk
status, we sought to compare the performance of an approach
based on inferred HLA types with the GRS. We utilized the
approach of Romanos et al. [21] on the Immunochip data, which
relies on both HLA types and 57 non-HLA Immunochip SNPs
(including one chrX SNP). Since directly measured HLA types
were not available for our datasets, we imputed HLA-DQA1 and
HLA-DQB1 haplotype alleles using HIBAG [35] and derived the
presence of DQ2.2/DQ2.5-homozygous/DQ2.5-heterozygous/
DQ8 heterodimer status. The coefficients for the HLA risk types
in the HLA+57 SNP model were not available for the Romanos et
al. method, thus we had to estimate these from our data. For
application of the GRS method, we trained models on 18,309
autosomal SNPs from UK2 (the subset shared between the
Illumina 670 and Immunochip) then externally validated these
models on the Immunochip data. We trained three separate
models: All autosomal SNPs, MHC SNPs, and autosomal non-
MHC SNPs. As seen in Figure 3b, the GRS trained on either all
SNPs or the MHC SNPs yielded higher AUC (0.87) than the
Romanos HLA+57 SNPs (AUC=0.85) or HLA type alone
(AUC=0.8). The predictive power of the GRS induced by SNPs
outside the MHC was lower but still substantial at AUC=0.72.
We also performed similar analyses on the rest of the datasets
(UK2 in cross-validation then externally validated on the rest),
comparing the GRS with the HLA type and with analysis of HLA
tag SNPs [36] commonly used to infer HLA types since the 57
Genomic Prediction of Celiac Disease
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Figure 1. The analysis workflow.
doi:10.1371/journal.pgen.1004137.g001
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non-HLA SNPs used by Romanos were not available on these
platforms. As shown in Figure S2, the HLA type approach had
consistently lower AUC (0.795–0.86) than analysis of the
individual HLA tag-SNPs of Monsuur (AUC of 0.85–0.876,
directly modeled using logistic regression on the SNPs in the UK2
then tested on the other datasets) and substantially lower than the
GRS (AUC of 0.86–0.894).
Overall, our results showed that the L1-penalized SVM
approach which modeled the SNPs directly was able to extract
more information from the HLA region than the coarse-grained
HLA haplotype model, either with or without the addition of the
57 non-HLA SNPs. This resulted in a gain in explained
phenotypic variance of 3.5% over the best Romanos et al model
in the Immunochip data.
Specificity of the Genomic Risk Score
We investigated whether the models of CD were predictive of
case/control status in other immune-mediated diseases, specifically
type 1 diabetes (T1D), rheumatoid arthritis (RA), and Crohn’s
Disease/Inflammatory Bowel Disease (Crohn’s) from the
WTCCC [37]. We utilized the 76,847 post-QC SNPs that
appeared on both the UK2 Illumina and WTCCC Affymetrix
500K arrays. Despite the substantial reduction in the number of
SNPs from the original data, we observed only small reductions in
AUC in the restricted UK2 dataset in cross-validation, indicating
that most of the predictive information was retained in the reduced
SNP set (AUC=0.85 at ,200 SNPs). The models trained on the
UK2 were subsequently tested on the T1D, RA and Crohn’s
datasets. We also used the Finnish CD dataset as external
validation to ensure that the high predictive performance observed
in cross-validation on UK2 was replicated on other CD datasets
and not degraded by using fewer SNPs. Overall, the models
showed some predictive ability of T1D (AUC=0.69), consistent
with previous findings showing shared genetics between T1D and
CD [38,39] (see Figure S3 for results for the MHC and non-MHC
SNPs in T1D) but displayed very low performance (AUC 0.51–
0.54) on the RA and Crohn’s datasets. In contrast, performance on
the Finnish CD cohort was only slightly lower (AUC=0.85)
Table 1. List of celiac disease datasets used in this study.
Name Ethnicity Platform
Autosomal SNPs
post-QC Male Female Cases Controls
Total samples
post-QC
Finn Finnish Illumina 513,952 1206 1270 647 1829 2476
IT Italian Illumina 515,641 332 708 497 543 1040
NL Dutch Illumina 515,169 752 897 803 846 1649
UK1 British Illumina 301,659 938 1262 778 1422 2200
UK2 British Illumina 515,444 2954 3831 1849 4936 6785
IMM British Immunochip 18,252* 3927 6377 5907 4397 10,304
*only SNPs in common with the post-QC UK2 dataset were analysed and are thus shown here.
doi:10.1371/journal.pgen.1004137.t001
Figure 2. Building genomic models predictive of celiac disease. LOESS-smoothed (a) AUC and (b) phenotypic variance explained, from 10610
cross-validation, with differing model sizes, within each celiac dataset. The grey bands represent 95% confidence intervals about the mean LOESS
smooth.
doi:10.1371/journal.pgen.1004137.g002
Genomic Prediction of Celiac Disease
PLOS Genetics | www.plosgenetics.org 5 February 2014 | Volume 10 | Issue 2 | e1004137
compared with the full SNP set, again confirming that the CD
models replicated across ethnic cohorts despite using a reduced set
of SNPs (Figure 3c).
Analysis of a Combined Dataset
All CD datasets showed consistently high AUC both in cross-
validation and in external validation, indicating that the risk of
substantial confounding of the case/control status by ethnic cohort
(via population stratification or strong intra-cohort batch effects)
was low. Therefore, in order to increase statistical power in
comparing the performance of the models, we created a combined
dataset consisting of the Finnish, Dutch, and Italian cohorts,
totaling 5158 samples (1943 cases and 3215 controls, 512,634
SNPs). This combined dataset is likely more representative of a
real screening scenario where individuals of different ethnicities
are being screened for CD. Figure 4a shows kernel density
Figure 3. Performance of the genomic risk score in external validation, when compared to other approaches, and on other related
diseases. ROC curves for models trained in the UK2 dataset and tested on (a) four other CD datasets, (b) the Immunochip CD dataset, comparing the
GRS approach with that of Romanos et al. [21], and (c) three other autoimmune diseases (Crohn’s disease, Rheumatoid Arthritis, and Type 1 Diabetes).
We did not re-tune the models on the test data. For (b) and (c), we used a reduced set of SNPs for training, from the intersection of the UK2 SNPs with
the Immunochip or WTCCC SNPs (18,252 SNPs and 76,847 SNPs, respectively). In (c), the same reduced set of SNPs was used for the CD-Finn dataset,
in order to maintain the same SNPs across all target datasets.
doi:10.1371/journal.pgen.1004137.g003
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estimates of the predicted risk scores for cases and controls in the
combined dataset, where the scores are based on models trained
on the UK2 dataset as previously described. As expected from the
high AUC, there is substantial separation between the score
distributions for the two classes. Also shown is the percentage of
the combined population corresponding to a range of GRS
thresholds (Figure 4b).
Positive and Negative Predictive Values under Different
Prevalence Settings
The prevalence of CD in the general population, here taken to
be 1%, is much lower than the prevalence in the case/control
datasets where the cases are substantially over-represented owing
to the study design. Considering the prevalence as the prior
probability of a person having the disease (without knowing their
genetic profile), then unless the likelihood of disease given the
genotype is high as well, the posterior probability of disease will
remain low. To quantify the predictive performance of our
models while accounting for the prevalence, we estimated the
precision of our models trained on UK2 on the Finn+NL+IT
combined dataset. We down-sampled the cases in the combined
dataset to simulate settings with different CD prevalence levels
(1%, 3%, 10%, and 20%) and estimated precision and sensitivity
in the test data, repeated in 50 independent simulations for each
prevalence level (Figure 5a). The precision here is equivalent to
the PPV [40] as the precision is estimated in data with the same
prevalence as assumed by the PPV. The PPV is the posterior
probability of having the disease given a positive diagnosis, and
the NPV is the posterior probability of not having the disease
given a negative diagnosis (a perfect model offers
PPV=NPV=1). Note that the lowest NPV achievable is
12prevalence which translates to seemingly high NPV values
in the low-prevalence setting, rendering NPV less useful for
assessing classifiers in such settings as even a weak classifier can
achieve apparently high NPV.
Population screening for CD is not currently accepted practice.
Most evidence supports an active case-finding strategy where patients
with risk-factors for CD, and therefore higher pre-test probability of
CD than the population-wide average, are identified by their
primary practitioner and screened. For example, the prevalence of
CD in patients with a first-degree relative with CD is 10% or higher
[41,42], and the prevalence of CD in patients with T1D ranges from
3–16% [43]. The increased CD prevalence in these groups of
patients improves the apparent ‘diagnostic’ performance of the GRS.
To examine the effect of prevalence on PPV, we first employed the
GRS in a population-based setting (prevalence of 1%) which resulted
in a PPV of ,18% at a threshold that identified 20% of the CD
cases, but this dropped to,3% at a threshold identifying 85% of the
CD cases. In contrast, performance in more clinically relevant
settings with higher CD prevalence was substantially better. For
instance, the PPV increased from,18% at 1% prevalence to,40%
at 3% prevalence, and to ,70% at 10% prevalence, with the
sensitivity setting at 20% (Figure 5a). At 10% prevalence, increasing
the GRS sensitivity to 60% resulted in a PPV of 40%, and at a
sensitivity of 80% the PPV was,30%. There were small differences
in the AUC between prevalence levels, on the order of 1–3%,
however all settings maintained high AUC at $0.86 (Figure 5b).
Since sensitivity and specificity are independent of prevalence, these
differences are likely due to the small number of cases in the low-
prevalence settings and stochastic variations in the data caused by
randomly sampling cases from different ethnicities, as each ethnicity
showed slightly different predictability of CD in external validation,
Figure 4. Distribution of genomic risk scores in cases and controls. (a) Kernel density estimates of the risk scores predicted using models on
UK2 and tested in the combined dataset Finn+NL+IT, for cases and controls. (b) Thresholds for risk scores in terms of population percent, with the top
more likely to be a CD and the bottom more likely to be non-CD.
doi:10.1371/journal.pgen.1004137.g004
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together with clinical heterogeneity resulting from different numbers
of cryptic cases in the controls of each cohort.
Non-Disease Cases Implicated per True Disease Case
Another way to quantify the usefulness of predictive models as
diagnostic tools is to evaluate the number of subjects without CD
that are incorrectly identified as potential CD cases per each true
CD diagnosis, and to do so at different levels of clinical risk
(prevalence). This measure is equivalent to the posterior odds of
not having CD given the genotypes (1 – PPV)/PPV, where a lower
number is better (fewer incorrect cases implicated per true CD
case). Figure 6 shows that at a sensitivity threshold to detect 20%
of CD cases, the odds of incorrectly implicating CD were ,7:1 at
prevalence of 1%, but this decreased to ,1:2 and ,1:5 at a
prevalence of 10% and 20%, respectively. Further, at 10% CD
prevalence the odds of incorrectly implicating CD were less than
1:1 while maintaining sensitivity of more than 30%, and for 20%
CD prevalence up to 80% of true CD cases could be detected with
such odds.
Application of the Genomic Risk Score
The application of the GRS is straightforward: once the SNPs in
the model have been genotyped for a given patient, the GRS can
be easily computed as the sum of the SNPs weights times the allele
dosages plus an intercept term (Methods and Table S1). Our
models consist of ,200 SNPs, hence the score can be easily
computed in a spreadsheet or with PLINK. Whereas the models
are fixed in the training phase, the interpretation of the scores
depends on the screening setting in which they are used since
selection of different risk thresholds leads to different false positive
and false negative rates. In other words, the same numerical risk
score may be interpreted differently in each setting, depending on
the performance criteria required by the clinician, such as a
minimum level of sensitivity or a maximum number of non-CD
implicated per true CD implicated.
Figure 7 illustrates how the GRS could be applied in two
commonly encountered but different clinical settings to (i) exclude
individuals at average (background) risk of CD with high
confidence, or to (ii) stratify individuals at higher risk of CD for
further confirmatory testing. In the first setting, in order to
optimize the NPV, a suitably low GRS threshold is selected,
leading to a relatively large proportion of the population being
considered as potentially at-risk of CD. An NPV of 99.6%
(comparable to HLA testing) can be achieved at the population-
wide 1% prevalence by setting a threshold corresponding to
designating 15% of the population as CD cases (PPV of 5%). In
the second setting, we modeled a scenario where the risk of CD is
increased (for instance in patients with suggestive symptoms or
clinical conditions) and risk stratification is sought to identify the
patients most likely to benefit from further definitive investigation
for CD. The prevalence of CD in those with higher-risk
symptoms is approximately 3% [3,44] and in first-degree relatives
of CD patients it is 10% [41,42]. In this second setting, we
highlight two extreme choices of threshold as an example of what
is achievable using the GRS at each prevalence level. The first
threshold is stringent, predicting only a small number of high-
confidence individuals as likely to have CD and subsequently
leading to low sensitivity but higher PPV. The second threshold is
low, implicating a larger number of individuals as likely to have
CD and leading to higher sensitivity at the expense of reduced
PPV.
More detailed results for a range of prevalence levels are
shown in Table S2. These consider different cutoffs of the risk
score expressed as a proportion of the population implicated
for CD. We used the proportion of the population rather than
proportion of the cases (sensitivity) to select risk thresholds
Figure 5. Performance at different prevalences and partial ROC curves. (a) Positive and negative predictive values and (b) partial ROC curves
for models trained on UK2 using 228 SNPs in the model, and tested on the combined Finn+NL+IT dataset. K represents the prevalence of disease in
the dataset and the curves are threshold-averaged over 50 replications. Note that precision is not a monotonic function of the risk score. Precision is
equivalent to PPV here. A prevalence of ,10% corresponds to prevalence in first-degree relatives of probands with CD [42].
doi:10.1371/journal.pgen.1004137.g005
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since the true number of cases is unknown and we must select
how to classify a given individual based only on their score
relative to the population scores estimated in our data
(Figure 4). As expected, sensitivity and specificity remain
unchanged between the prevalence levels using the same risk
score cutoff, however PPV, NPV and consequently the number
of people incorrectly implicated as CD for each true CD case,
depend strongly both on the prevalence and on the cutoff.
Therefore, at a given prevalence level a suitable risk score
cutoff can be selected in order to balance the two competing
requirements of increasing the number of people correctly
identified as having CD per true cases (PPV) while maintaining
an acceptable level of sensitivity (coverage of the cases). A
major benefit of the GRS is its flexibility in adapting to the
appropriate clinical scenario and needs of the clinician. The
PPV of the GRS can be adjusted up or down by varying the
GRS cutoff and considering the acceptable level of sensitivity
to detect CD. In practice, the most clinically appropriate cut-
off thresholds would ideally be determined in local populations
by undertaking prospective validation studies utilizing the
GRS (See Discussion).
Risk Score Calibration
While the raw GRS cannot strictly be interpreted as the
probability of disease given the genotypes, since it hasn’t been
normalized to be between 0 and 1, the score can be transformed
Figure 6. Clinical interpretation as a function of threshold and prevalence. The number of non-CD cases ‘‘misdiagnosed’’ (wrongly
implicated by GRS) per true CD cases ‘‘diagnosed’’ (correctly implicated by GRS), for different levels of sensitivity. The risk score is based on a model
trained on the UK2 dataset, and tested on the combined Finn+NL+IT dataset. The results were threshold-averaged over 50 independent replications.
Note that the curve for K= 1% does not span the entire range due to averaging over a small number of cases in that dataset.
doi:10.1371/journal.pgen.1004137.g006
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into a probability using the empirical distribution of scores in the
data (Figure 4). To assess the agreement between the predicted
probability of disease and the observed probability of disease, we
used calibration plots [45] that compared the predicted 5%
quantiles of the risk scores, derived from models trained on the
UK2 dataset and externally applied to the other datasets, with the
observed probability of cases in each bin. For a well-calibrated
GRS, the proportion of cases to samples in each bin should be
approximately equal to the predicted risk. To correct for potential
lack of calibration, we fitted a LOESS smooth to the calibration
curve, which was then used to adjust the raw predictions into
calibrated predictions. To avoid biasing the calibration step and to
assess how well it performed in independent data, we randomly
split each external dataset (Finn, IT, NL, and UK1) into two
halves of approximately equal size. We assessed calibration in the
first half of each dataset and fitted a LOESS smooth to the
calibration curve (Figures S4a and S4c). We then used the LOESS
smooth to calibrate the predictions for the other half of each
dataset and assessed the calibration there (Figures S4b and S4d).
Since the calibration is affected by prevalence, we assessed this
procedure both in the observed data (prevalence of ,40%) and in
a subsampled version with prevalence of ,10%. Overall, our
calibration procedure was able to correct for a substantial amount
of mis-calibration in the raw scores, even in the more challenging
case of 10% prevalence.
Discussion
In this study, we have sought to exploit the strong genetic basis
for CD and leverage comprehensive genome-wide SNP profiles
using statistical learning to improve risk stratification and the
diagnosis of CD. Our models showed excellent performance in
cross-validation and were highly replicable in external validation
across datasets of different ethnicities, suggesting that the genetic
component is shared between these European ethnicities and that
our models were able to capture a substantial proportion of it.
Figure 7. Example clinical scenarios. The GRS can be employed in different clinical scenarios and tuned to optimize outcomes. The GRS can be
employed in a comparable manner to HLA testing (left table) to confidently exclude CD. In this scenario, we selected a GRS threshold based on
NPV= 99.6% however a range of thresholds can be selected to achieve a high NPV (see note below). The GRS can also stratify CD risk (right table).
Confirmatory testing (such as small bowel biopsy) would be reserved for those at high-risk. In this example, we present two scenarios: optimization of
PPV or of sensitivity. In comparison to the GRS, all HLA-susceptible patients will need to undergo further confirmatory testing for CD. For more
information on GRS performance across a range of thresholds, see Table S2. Prospective validation of the GRS in local populations would enable the
most appropriate settings for NPV, PPV and sensitivity to be identified which provide the optimal diagnostic outcomes. + The highest achievable NPV
at 10% prevalence was 99.4%.
doi:10.1371/journal.pgen.1004137.g007
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Importantly, even without explaining a majority of CD heritabil-
ity, the models were robust and accurate, showing that it is not
necessary to explain most of the heritability in order to produce a
useful model.
The most frequently employed tools to diagnose CD are
serology and small bowel histology, but both have limitations.
Differences in the sensitivity of antibody recognition of commer-
cially employed CD-specific antigens such as tissue transglutamin-
ase, deamidated gliadin peptides, and endomysial antigen, as well
as the human operator performing the assay can all influence
findings and affect reproducibility of serological testing [9,46–49].
Serologic testing in children is reported to be less reliable before
the age of 4 and up to 50% of children normalize elevated
antibodies over time [50,51]. While small bowel histology remains
the ‘gold standard’ confirmatory test, it is dependent upon patients
willing and available to undergo endoscopy, adequate sampling by
the gastroenterologist, and appropriate pathological processing
and interpretation [52–54]. The frequencies of false positives and
false negatives in CD serology assays vary widely and also partly
depend upon what degree of histologic inflammation is considered
compatible with CD [52,54–58]. Notably, the accuracy of both
serologic and histologic testing for CD is dependent on the
ongoing consumption of gluten. It is clear that clinically significant
variability exists in serologic and histologic work-up for CD and
new tools to improve the accuracy of CD diagnosis would be of
benefit to clinicians. Given the strong genetic basis for CD,
genomic tools are logical and appealing because they are relatively
robust and less subject to the kind of variability seen with serologic
and histologic assessment, are independent of age, and do not rely
on dietary intake of gluten.
A major shortcoming of clinical HLA typing for risk prediction
of CD is its poor specificity. HLA testing would result in virtually
all CD cases detected but at the cost of approximately 30–56
people incorrectly implicated for each true case of CD. A
significant advantage of the GRS approach is that it can be
adapted to the clinical scenario in order to maximize PPV and
diagnostic accuracy. By promoting accurate clinical stratification,
the GRS could reserve invasive and more expensive confirmatory
testing for those who would most likely benefit from further
investigation to secure a diagnosis, and it would avoid unnecessary
procedures in those who are HLA susceptible but unlikely to have
CD. This provides both clinical and economic benefits. HLA
typing does not provide the flexibility afforded by the GRS and
cannot be effectively employed to identify those who would benefit
from endoscopy. For instance, if HLA typing were used as a guide
for further investigations, at 10% CD prevalence it would generate
over five unnecessary endoscopies per correct endoscopy and at
1% CD prevalence it would generate 30–56 unnecessary
endoscopies. Small bowel endoscopy is not a trivial undertaking
– the procedure is costly (approximately AUD $750–$1000 for the
procedure and associated pathology), has potential complications,
necessitates a full day off work, and many patients are reluctant to
undergo it.
The GRS can be used to exclude patients unlikely to have
CD with a performance comparable to HLA typing. Testing
with these parameters may be useful in the clinical scenario of
assessing individuals at average risk of CD. A common example
would be when a person has commenced a gluten-free diet prior
to assessment for CD by serology or small bowel examination
and are unwilling or unable to resume oral gluten intake in
order to make testing reliable. This is an increasingly common
clinical dilemma as the number of people following a gluten-
free diet without adequate initial testing for CD continues to
rise. In the United States approximately 30% of the adult
population are interested in cutting back or avoiding dietary
gluten [59].
The GRS can also be used to stratify the risk for CD in
patients who present with suggestive clinical features. These risk
factors include having a first-degree relative with CD or
problems such as recurrent abdominal pain, bloating, diarrhea
or constipation, fatigue, weight loss, unexplained anemia,
autoimmune disease (including thyroid disease, T1D, autoim-
mune hepatitis, rheumatoid arthritis, and Sjogren’s syndrome),
infertility or early-onset osteoporosis [3,60]. Supporting the
recently revised diagnostic guidelines for CD, which promote
HLA testing as the 1st line investigation for higher-risk cases,
genetic testing of CD is likely to be more informative in these
sub-populations exhibiting higher-than-normal prevalence.
While clinical guidelines recommend screening for CD in these
high-risk populations [61], testing often poses a diagnostic
dilemma as serologic assessment alone cannot confidently
exclude a diagnosis, especially given the higher pre-test
probability. HLA typing is not particularly informative as the
CD HLA susceptibility haplotypes HLA-DQ2.5 and DQ8 are
commonly present (manifesting in over 90% of patients with
T1D and in 65% in first-degree relatives of individuals with CD)
[62,63]. Stratifying these higher-risk patients based on a GRS
will allow improved identification of those where small bowel
biopsy is likely to be informative. Thus, a GRS should reduce
the number of unnecessary small bowel biopsies in first-degree
relatives who carry HLA susceptibility for CD but do not have
it. We have found that our CD models had only moderate
predictive ability for T1D, which is consistent with previous
findings showing some shared genetics between T1D and CD
[38]. Despite the substantial overlap of genetic factors for
autoimmune disease, the CD models had negligible predictive
ability for Crohn’s disease and rheumatoid arthritis. These
results indicate that our GRS is specific to CD and less likely to
incorrectly identify patients with other autoimmune diseases as
having CD, but further work is required to determine whether
CD can be as confidently predicted in individuals with T1D as it
is in non-T1D populations.
Another major clinical challenge that may benefit from
genomic risk prediction is determining the natural history of
potential CD (formerly termed ‘latent CD’) when there is
serologic but not histologic evidence of CD, and identifying
which patients are more likely to develop overt CD with small
bowel inflammation [64]. Current practice is to follow-up all
patients with immunologic evidence of gluten intolerance in order
to capture those who will eventually develop overt disease. An
analogous clinical scenario is that of children with positive CD
serology, of whom 50% will fail to develop small bowel changes
consistent with CD during follow-up [50,51]. In both clinical
situations, it is reasonable to expect that a GRS can improve risk
stratification of such patients for developing overt CD. Of course,
environmental factors are important in the development of CD
and the exact extent to which environmental versus genetic
factors contribute to the development of overt CD remains
unknown. Long-term follow-up studies of patients with potential
CD will be necessary to establish the role of genomic risk
prediction in this important subgroup.
Future work will look at optimizing our GRS as a tool to predict
CD risk. Validation of our model in real-life practice will be
important to confirm the clinical benefit of the GRS in
conjunction with serology and/or over HLA typing alone, as well
as to what extent other clinical predictors such as sex, age, and
family history can contribute to clinically relevant risk prediction.
Future prospective studies will enable direct optimization of
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clinical utility (accuracy, practicality, throughput and cost)
afforded by the GRS, for example in conjunction with CD
serology. These studies will also provide a rigorous evidence base
for suggested clinical guidelines of GRS usage. Importantly,
appropriate GRS cut-off levels to maximize diagnostic accuracy
(optimal PPV and NPV for each given clinical scenario and CD
prevalence) could be obtained by local prospective validation.
Such studies can identify the ultimate clinical role for the GRS:
whether it can effectively replace HLA typing and also whether it
is a stand-alone test or one to accompany CD serology. Hadithi et
al showed that in patients at high-risk of CD the addition of HLA
typing to CD serology had the same performance as either testing
strategy alone [65], but the greater precision of the GRS over
HLA typing may better complement CD serology. Understanding
where the GRS fits in the diagnostic algorithm to optimize
precision and cost-effectiveness will be essential, as is the role it
might play in the diagnostic work-up of CD in populations with
lower levels of clinical risk. Health economic modeling will address
the cost-benefits of using the GRS in the diagnosis of CD, taking
into account the cheaper cost of GRS over HLA typing, and
include the downstream benefits of potentially reducing endosco-
pies (substantial cost savings and value to patients from reduced
discomfort) as well as potential improvements in quality of life
from the detection of CD.
Further, it may be that other statistical modeling approaches
yield improvements in predictive power, for example non-additive
models that consider epistatic interactions between SNPs. Another
avenue for improvement is considering each CD subtype
separately, recognizing potentially different genetic bases for these
conditions. Based on our results, we do not expect substantial
improvements from increasing sample size alone, however this will
be important for adequately powered studies of lower frequency
genetic variants of assumedly greater effect size.
In summary, this study demonstrates that simultaneous
modeling of all SNPs using statistical learning was able to
generate genomic risk scores that accurately predict CD to a
clinically relevant degree. This was despite the models
explaining only a minority of disease heritability. The GRS
better enables clinicians to stratify patients according to their
risk of CD compared to HLA typing alone and, we predict,
more accurately determines those suitable for confirmatory
testing in the form of small bowel biopsy. Reserving this
invasive, time consuming and costly procedure for higher-risk
cases is likely to improve the accuracy, cost and public
acceptance of testing for CD, and by extension, benefit the
overall diagnosis of CD in the community. By better prioritizing
higher-risk patients for confirmatory testing, genomic risk
prediction carries promise as a clinically useful tool to add to
the clinician’s diagnostic armamentarium. Ultimately, we
envisage a clinical scoring algorithm based on the combination
of clinical features, serologic, and genetic information that will
accurately predict people with biopsy-confirmed CD and
perhaps ultimately overcome the reliance on small bowel
histology altogether. Further, the costs of genotyping a select
number of marker SNPs with a low-plex, high throughput
technology are already far lower than the costs of full HLA
typing, resulting in a test that is cheaper, more flexible and
more precise than HLA typing. More generally, this study
demonstrates that statistical learning approaches utilizing SNPs
can already produce useful predictive models of a complex
human disease using existing genotyping platforms assaying
common SNPs and suggests that similar approaches may yield




All participants gave informed consent and the study protocols
were approved by the relevant institutional or national ethics
committees. Details given in references van Heel et al [23] and
DuBois et al [24]. All data was analysed anonymously.
Data
We analyzed six CD datasets: UK1 [23], UK2, IT, NL, and Finn
[24], and IMM [66]. The main characteristics of the datasets are
listed in Table 1. In addition we used three WTCCC datasets
(T1D, Crohn’s, and RA) that have been described elsewhere
[30,37]. UK1 used the Illumina Hap330v1-1 array for cases and
Hap550-2v3 for controls, UK2 used the Illumina 670-QuadCus-
tom-v1 for cases and 1.2M-DuoCustom-v1 for controls, the NL
and IT datasets used the Illumina 670-QuadCustom-v1 in both
cases and controls, and the Finn dataset used the Illumina 670-
QuadCustom-v1 for cases and Illumina 610-Quad for controls.
The WTCCC data (T1D, Crohn’s, and RA) used the Affymetrix
500K array. In all of our models, we used autosomal SNPs only,
and did not include the gender as a covariable, as models built
separately on the two genders using the same sample size and
case:control balance showed very similar performance in cross-
validation on the UK2 dataset (results not shown). For analyses of
the MHC region, we defined the MHC as all SNPs on chr6 in the
range 29.7 Mb–33.3 Mb.
Quality Control
For each of the UK1, UK2, IT, NL, and Finn datasets, we
removed non-autosomal SNPs, SNPs with MAF,1%, with
missingness .1%, and those with deviations from Hardy-
Weinberg Equilibrium in controls P,561026. We also removed
samples with missingness .1%. We tested identity-by-descent
between samples in UK1 and UK2 and removed one of a pair of
samples with pi-hat $0.05 (either between the datasets or within
the datasets). The QC for the IMM Immunochip data has been
previously described [66]; we estimated 5763 Immunochip
samples to have pi-hat $0.125 (PLINK IBS) with any UK2
sample, and those were removed, leaving 10,304 Immunochip
samples in total, with 18,252 SNPs shared with the UK2 dataset
(post-QC). The QC for the WTCCC data (T1D, Crohn’s, and
RA) has been previously described [30,37].
Assessment of Population Structure Effects
To assess the impact of potential cryptic population structure,
we estimated the top 10 principal components (PCs) for the UK2
with EIGENSOFT 4.2 [67], after removal of regions with high LD
(see Text S1 for details). The principal components themselves
showed almost no predictive ability (AUC=0.52), and models
trained on all SNPs accounting for these PCs showed indistin-
guishable performance from the non-adjusted model, both in
cross-validation on the UK2 dataset and in external validation on
the Finn, NL, and IT datasets (Figure S5), demonstrating that
confounding of our UK2 models by population structure was
negligible and was not a contributing factor to the high predictive
ability.
Statistical Analysis
We used L1-penalized support vector machines (SVM)
implemented in the tool SparSNP [26] (https://github.com/
gabraham/SparSNP) as the classifiers. The L1-penalized SVM
is a sparse linear model, that is, many or most of the SNPs will
receive zero weight in the model, as determined by the L1
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penalty. The use of a sparse model fits with our prior
expectation that in autoimmune disease most SNPs will not be
associated with disease status. The inherent sparsity of the
model obviates the need for subsequent filtering of SNPs by
weight, in order to decide which ones show strong evidence of
association and which are spurious, as would be required in a
non-sparse (L2-penalized) model. In addition, in extensive
simulation and in analysis of real genotype data, including the
two celiac disease datasets UK1 and UK2, we have previously
shown the advantage of L1-penalized SVMs over commonly
used approaches such as polygenic scores (sum of the log odds),
linear mixed models (GCTA), and unpenalized logistic regres-
sion [30]. The advantage of sparse models over standard linear
mixed models in predicting autoimmune disease has been
recently confirmed in type-1 diabetes as well [68]. We have also
shown that our L1-penalized SVMs achieved essentially
identical performance to L1-penalized logistic regression
(glmnet) in cross-validation over the Finnish subset of the celiac
disease dataset, while being substantially faster [26]. Unlike
single marker approaches that estimate the effect size of each
SNP separately, the L1-penalized SVM is a multivariable
model, where the estimated effect of each SNP is conditional on
all other SNPs, thereby implicitly accounting for the linkage
disequilibrium (LD) between SNPs. Besides imposing sparsity,
the L1 penalty tends to produce models where one represen-
tative SNP is selected out of a group of highly correlated SNPs,
while the rest remain with a zero weight, in contrast with L2-
penalized or unpenalized models where many or all of these
SNPs may receive a non-zero weight. For an in-depth discussion
of these issues and the effects of varying LD levels on the
performance of multivariable models, see [30].
The L1-penalized SVM model is induced by minimizing the














where xi is the p-vector of genotypes for the ith sample in allele-
dosage coding {0, 1, 2}, y are the binary phenotypes {21, +1},
b is the p-vector of weights, b0 is the intercept (also called the
bias, which is not penalized), and l is the L1 penalty. We also
investigated adding an L2 penalty to the model (elastic-net),
however, based on initial cross-validation experiments, we
found no advantage in the L2 penalty and subsequently did
not use it. All of our models were additive in the allele dosage
{0, 1, 2}.






where the continuous value y^i is later thresholded at different
values to produce a binary predicted class. The model was
evaluated over a grid of penalties, in 10-fold cross-validation,
repeated 10 times. The optimal number of SNPs in the model was
decided based on the model with the highest average AUC across
the replications. The final model was a consensus model, averaged
over all 10610= 100 models, and containing approximately the
number of SNPs determined earlier. Post processing and plotting
of the results was performed in R [69], together with the package
ggplot2 [70].
Measures of Predictive Performance
To quantify the predictive performance of the models in cross-
validation and external validation, we employed receiver operating
characteristic (ROC) curves (sensitivity versus 1 minus specificity),
the area under the ROC curve (AUC) [71], and the proportion of
phenotypic variance explained [32].
To quantify predictive performance in different population
settings, we used the positive and negative predictive values, which








where ‘‘sens’’ is the sensitivity =TP/(TP+FN), ‘‘spec’’ is the
specificity =TN/(FP+TN), and ‘‘prev’’ is the population preva-
lence. The PPV/NPV are equivalent to the posterior probability
of a person having/not having the disease given a positive/
negative diagnosis, respectively. When the PPV and precision are
estimated in data with identical prevalence (that is, the observed
prevalence in the data is identical to the prevalence in the
population for which we wish to estimate PPV), they are
equivalent. Precision is defined as TP/(TP+FP).
Supporting Information
Figure S1 LOESS-smoothed AUC in 10610-fold cross-valida-
tion for the random subsamples of the UK2 dataset, in increasing
sample size proportions of the original data (n = 6785).
(EPS)
Figure S2 Results of externally validating the predictive
models, trained on UK2 in cross-validation, and tested on the
other CD datasets. Legend: Romanos HLA: 3-levels of risk (low,
medium, high) [21] based on imputed HLA type (HIBAG);
Romanos HLA+57 SNPs (Immunochip only): 3-level HLA risk plus
57 Immunochip non-HLA SNPs [21]; Monsuur HLA SNPs: logistic
regression on individual HLA SNPs [36] (5/6 SNPs or proxies
thereof were found in the UK2/Finn/NL/IT datasets, 3/6 were
found in the subset of UK1 shared with UK2); GRS MHC SNPs:
SparSNP run on individual SNPs on chr6 within 29.7
Mb–33.3 Mb; GRS non-MHC SNPs: SparSNP run on individual
autosomal SNPs outside MHC; GRS all SNPs: SparSNP run on all
autosomal SNPs.
(EPS)
Figure S3 ROC curves for CD model trained on SNP subsets of
the UK2 dataset that were assayed for the WTCCC-T1D dataset:
All SNPs (76,847 SNPS),MHC SNPs (186 SNPs in the MHC region
of chr6, 29.7–33.3 Mb), and Non-MHC SNPs (76,661 SNPs outside
the MHC).
(EPS)
Figure S4 Calibration plots, comparing predicted score in 5%
quantiles against observed proportions of cases falling within the
bin. The score comes from models trained on the UK2 dataset,
and tested on the rest of the datasets. The bars show 95%
confidence intervals using the Agresti-Coull method for
proportions. We randomly split the test datasets into two halves.
In the first half, we plotted the original quantiles of the scores
and fitted a LOESS smooth to them. We did this for the original
case/control data (prevalence of 40%), shown in (a), and for a
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subsampled version of the data with prevalence of 10% (c). We
then used the LOESS smooth to correct the original quantiles,
forming a calibrated score, one for each dataset (Finn, IT, NL,
UK1), which was then applied to the second half of the data,
shown in (b) and (d) for prevalence of 40% and 10%
respectively. The second half of the data was not used in the
calibration step.
(EPS)
Figure S5 (a) LOESS-smoothed AUC from 10-fold cross-
validation for the UK2 model (all autosomal SNPs), accounting
for the top 10 PCs (included in training but not in testing). (b)
External validation of the best UK2 model that accounted for the
PCs (PCs excluded from testing).
(EPS)
Table S1 The predictive model. The SNPs are sorted in
decreasing order of the absolute value of their model weight
averaged over the 10610 cross-validation folds. Stability is the
percentage of times a SNP was selected to have non-zero weight
over the 10610-cross-validation folds. Intercept: 20.757226. To
annotate the SNPs we used Bioconductor 2.12 together with the
packages VariantAnnotation 1.6.5 and TxDb.Hsapien-
s.UCSC.hg18.knownGene 2.9.0. We considered a SNP to be
genic if it was annotated to fall inside one of the regions
{spliceSite, intron, fiveUTR, threeUTR, coding, promoter} and
intergenic otherwise. For intergenic SNPs, we also annotate the
nearest gene and the distance to it. All positions are in hg18
coordinates.
(PDF)
Table S2 Summary of screening results at different prevalence
levels for the combine dataset Finn+IT+NL dataset, using different
cutoffs to declare the samples as disease cases (expressed as % of
the population). The smaller the cutoff, the stricter the definition of
a disease case.
(PDF)
Text S1 Supplementary Methods.
(PDF)
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